ArticleFrontiers in bioscience (Elite edition)2011
Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy.
Article in Frontiers in bioscience (Elite edition), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Assessing the impact of gestational age of donors on the efficacy of amniotic epithelial cell-derived extracellular vesicles in experimental bronchopulmonary dysplasia.Stem cell research & therapy · 2022Article
- Revascularization of chronic total occlusion coronary artery and cardiac regeneration.Frontiers in cardiovascular medicine · 2022Review
- Influence of AutologousInternational journal of fertility & sterility · 2021Article
- Are We Ready for Cell Therapy to Treat Stroke?Frontiers in cell and developmental biology · 2021Review
- Human Endothelial Colony Forming Cells Express Intracellular CD133 that Modulates their Vasculogenic Properties.Stem cell reviews and reports · 2019Article
- GMP-conformant on-site manufacturing of a CD133Stem cell research & therapy · 2017Article
- Cell Therapy for Refractory Angina: A Reappraisal.Stem cells international · 2017Review
- Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.American heart journal · 2016Article
- Full GMP-compliant validation of bone marrow-derived human CD133(+) cells as advanced therapy medicinal product for refractory ischemic cardiomyopathy.BioMed research international · 2015Article
- CD133: a stem cell biomarker and beyond.Experimental hematology & oncology · 2013Article
- Cardiac stem cells and their roles in myocardial infarction.Stem cell reviews and reports · 2013Review
- Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation?Stem cells translational medicine · 2012Review
- Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.International archives of medicine · 2012Article
- Wound Healing Angiogenesis: Innovations and Challenges in Acute and Chronic Wound Healing.Advances in wound care · 2012Review
- Myocardial restoration: is it the cell or the architecture or both?Cardiology research and practice · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.